

**ITCH Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13626c****Specification****ITCH Antibody (Center) Blocking peptide - Product Information**

Primary Accession [Q96J02](#)

**ITCH Antibody (Center) Blocking peptide - Additional Information****Gene ID 83737****Other Names**

E3 ubiquitin-protein ligase Itchy homolog, Itch, 632-, Atrophin-1-interacting protein 4, AIP4, NFE2-associated polypeptide 1, NAPP1, ITCH

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13626c was selected from the Center region of ITCH. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**ITCH Antibody (Center) Blocking peptide - Protein Information****Name ITCH****Function**

Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:<a href="http://www.uniprot.org/citations/14602072" target="\_blank">14602072</a>, PubMed:<a href="http://www.uniprot.org/citations/17028573" target="\_blank">17028573</a>, PubMed:<a href="http://www.uniprot.org/citations/16387660" target="\_blank">16387660</a>, PubMed:<a href="http://www.uniprot.org/citations/18718448" target="\_blank">18718448</a>, PubMed:<a href="http://www.uniprot.org/citations/18718449" target="\_blank">18718449</a>, PubMed:<a href="http://www.uniprot.org/citations/11046148" target="\_blank">11046148</a>, PubMed:<a href="http://www.uniprot.org/citations/19592251" target="\_blank">19592251</a>, PubMed:<a href="http://www.uniprot.org/citations/19116316" target="\_blank">19116316</a>, PubMed:<a href="http://www.uniprot.org/citations/19881509" target="\_blank">19881509</a>, PubMed:<a href="http://www.uniprot.org/citations/20491914" target="\_blank">20491914</a>,

PubMed:<a href="http://www.uniprot.org/citations/20392206" target="\_blank">20392206</a>, PubMed:<a href="http://www.uniprot.org/citations/20068034" target="\_blank">20068034</a>, PubMed:<a href="http://www.uniprot.org/citations/23146885" target="\_blank">23146885</a>, PubMed:<a href="http://www.uniprot.org/citations/24790097" target="\_blank">24790097</a>, PubMed:<a href="http://www.uniprot.org/citations/25631046" target="\_blank">25631046</a>, PubMed:<a href="http://www.uniprot.org/citations/15051726" target="\_blank">15051726</a>). Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation (PubMed:<a href="http://www.uniprot.org/citations/17028573" target="\_blank">17028573</a>, PubMed:<a href="http://www.uniprot.org/citations/18718448" target="\_blank">18718448</a>, PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>, PubMed:<a href="http://www.uniprot.org/citations/19881509" target="\_blank">19881509</a>). Involved in the control of inflammatory signaling pathways (PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>). Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways (PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>). Promotes the association of the complex after TNF stimulation (PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>). Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains (PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>). This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFkB1 (PubMed:<a href="http://www.uniprot.org/citations/19131965" target="\_blank">19131965</a>). Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways (PubMed:<a href="http://www.uniprot.org/citations/19592251" target="\_blank">19592251</a>). Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response (PubMed:<a href="http://www.uniprot.org/citations/18718448" target="\_blank">18718448</a>, PubMed:<a href="http://www.uniprot.org/citations/20491914" target="\_blank">20491914</a>). Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages (PubMed:<a href="http://www.uniprot.org/citations/18718448" target="\_blank">18718448</a>). Mediates JUN ubiquitination and degradation (By similarity). Mediates JUNB ubiquitination and degradation (PubMed:<a href="http://www.uniprot.org/citations/16387660" target="\_blank">16387660</a>). Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation (By similarity). Involved in the negative regulation of MAVS-dependent cellular antiviral responses (PubMed:<a href="http://www.uniprot.org/citations/19881509" target="\_blank">19881509</a>). Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation (PubMed:<a href="http://www.uniprot.org/citations/19881509" target="\_blank">19881509</a>). Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity (PubMed:<a href="http://www.uniprot.org/citations/23146885" target="\_blank">23146885</a>). Ubiquitinates PI4K2A and negatively regulates its catalytic activity (PubMed:<a href="http://www.uniprot.org/citations/23146885" target="\_blank">23146885</a>). Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM (PubMed:<a href="http://www.uniprot.org/citations/14602072" target="\_blank">14602072</a>, PubMed:<a href="http://www.uniprot.org/citations/23146885" target="\_blank">23146885</a>, PubMed:<a href="http://www.uniprot.org/citations/34927784" target="\_blank">34927784</a>). Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination (PubMed:<a href="http://www.uniprot.org/citations/17028573" target="\_blank">17028573</a>, PubMed:<a href="http://www.uniprot.org/citations/18628966" target="\_blank">18628966</a>, PubMed:<a href="http://www.uniprot.org/citations/23886940" target="\_blank">23886940</a>). Ubiquitinates SNX9 (PubMed:<a href="http://www.uniprot.org/citations/20491914" target="\_blank">20491914</a>).

target="\_blank">>20491914</a>). Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation (By similarity). Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP (PubMed:<a href="http://www.uniprot.org/citations/20068034" target="\_blank">20068034</a>). Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID (PubMed:<a href="http://www.uniprot.org/citations/20392206" target="\_blank">20392206</a>). Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:<a href="http://www.uniprot.org/citations/25631046" target="\_blank">25631046</a>). Inhibits the replication of influenza A virus (IAV) via ubiquitination of IAV matrix protein 1 (M1) through 'Lys-48'-linked conjugation resulting in M1 proteasomal degradation (PubMed:<a href="http://www.uniprot.org/citations/30328013" target="\_blank">30328013</a>). Ubiquitinates NEDD9/HEF1, resulting in proteasomal degradation of NEDD9/HEF1 (PubMed:<a href="http://www.uniprot.org/citations/15051726" target="\_blank">15051726</a>).

### **Cellular Location**

Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm. Nucleus Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Endosome membrane; Peripheral membrane protein; Cytoplasmic side. Note=May be recruited to exosomes by NDFIP1 (PubMed:18819914). Localizes to plasma membrane upon CXCL12 stimulation where it co-localizes with CXCL4 (PubMed:14602072) Localization to early endosomes is increased upon CXCL12 stimulation where it co-localizes with DTX3L and CXCL4 (PubMed:24790097)

### **Tissue Location**

Widely expressed.

### **ITCH Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **ITCH Antibody (Center) Blocking peptide - Images**

### **ITCH Antibody (Center) Blocking peptide - Background**

Atrophin-1 contains a polyglutamine repeat, expansion of which is responsible for dentatorubral and pallidoluysian atrophy. The protein encoded by this gene interacts with atrophin-1. This encoded protein is a closely related member of the NEDD4-like protein family. This family of proteins are E3 ubiquitin-ligase molecules and regulate key trafficking decisions, including targeting of proteins to proteasomes or lysosomes. This encoded protein contains four tandem WW domains and a HECT (homologous to the E6-associated protein carboxyl terminus) domain. It can act as a transcriptional corepressor of p45/NFE2 and may participate in the regulation of immune responses by modifying Notch-mediated signaling. It is highly similar to the mouse Itch protein, which has been implicated in the regulation and differentiation of erythroid and lymphoid cells.

### **ITCH Antibody (Center) Blocking peptide - References**

Yang, F., et al. Cell Death Differ. 17(8):1354-1367(2010) Baumann, C., et al. FEBS J. 277(13):2803-2814(2010) Venuprasad, K. Cancer Res. 70(8):3009-3012(2010) Lohr, N.J., et al. Am. J. Hum. Genet. 86(3):447-453(2010) Ushijima, Y., et al. Virol. J. 7, 179 (2010) :